Differential Clearance of Rat and Human Bone Marrow-Derived Mesenchymal Stem Cells from the Brain after Intra-arterial Infusion in Rats

Abstract

Intra-arterial (IA) delivery of bone marrow-derived mesenchymal stem cells (BM-MSCs) has shown potential as a minimally invasive therapeutic approach for stroke. The aim of the present study was to determine the whole-body biodistribution and clearance of technetium-99m (^99mTc)-labeled rat and human BM-MSCs after IA delivery in a rat model of transient middle cerebral artery occlusion (MCAO) using single-photon emission computed tomography (SPECT). Our hypothesis was that xenotransplantation has a major impact on the behavior of cells. Male RccHan: Wistar rats were subjected to sham operation or MCAO. Twenty-four hours after surgery, BM-MSCs (2×10⁶ cells/animal) labeled with ^99mTc were infused into the external carotid artery. Whole-body SPECT images were acquired 20 min, 3 h, and 6 h postinjection, after which rats were sacrificed, and organs were collected and weighed for measurement of radioactivity. The results showed that the majority of the cells were located in the brain and especially in the ipsilateral hemisphere immediately after cell infusion both in sham-operated and MCAO rats. This was followed by fast disappearance, particularly in the case of human cells. At the same time, the radioactivity signal increased in the spleen, kidney, and liver, the organs responsible for destroying cells. Further studies are needed to demonstrate whether differential cell behavior has any functional impact.

Keywords

Intra-arterial (IA) delivery Biodistribution Bone marrow-derived mesenchymal cells (BM-MSCs)Cerebral ischemia Single-photon emission computed tomography (SPECT) imaging Xenografting

Introduction

Stroke is the most common reason for adult disability (6). At present, the only pharmacological agent approved for treating acute ischemic stroke is tissue plasminogen activator, but due to its narrow therapeutic window of 4.5 h it can be used for only 2–4% of ischemic stroke patients (24). Thus, there is an urgent need for an effective treatment with a wider therapeutic window. Cell-based therapies have emerged as a promising approach and may present noteworthy health benefits for stroke patients (4,27). Cell-based therapies may act at least partly through regenerative mechanisms, such as neurogenesis, angiogenesis, and synaptogenesis (13,22).

A particularly attractive method is intravascular cell delivery because it is a noninvasive and an effective administration route that is suitable for large or multiple infarcts (33). To understand how therapeutic cells work after systemic infusion, it is crucial to follow their whole-body distribution, kinetics, and engraftment patterns within the target tissue. We have previously shown that human umbilical cord blood cells and human embryonic stem cell-derived neural progenitors accumulated primarily in the lungs after intravenous (IV) infusion in rats subjected to middle cerebral artery occlusion (MCAO). Lung accumulation was followed by cellular relocation to the liver and spleen with no major sign of engraftment in the brain (16,24). The lung entrapment pattern seems to depend on cell size and active cell surface adhesion mechanisms (11,16). Fortunately, it is possible to circumvent entrapment by filtration organs through targeting the cells directly to the ischemic brain by using intra-arterial (IA) delivery. IA infusion of ¹¹¹In-oxine-labeled human bone marrow-derived mesenchymal stem cells (BM-MSCs) has resulted in immediate and efficient cell entrapment in the brain (23). However, again most of the signals disappeared from the brain and relocated to the liver and spleen during the next 24 h.

The aim of the present study was to compare rat and human BM-MSCs in sham-operated and MCAO rats during the first hours after IA delivery. Our hypothesis was that xenografting might have an impact on the engraftment and clearance of cells.

Materials and Methods

Animals

Male RccHan: Wistar rats (weight 246–343 g, age 3–4 months) were purchased from Harlan Laboratories (Horst, The Netherlands) and quarantined for 2 weeks prior to the experiment. The animals were housed individually after surgery in Scantainer (Scanbur, Sollentuna, Sweden) cages (temperature 21 ± 1°C, humidity 50–60%, light period 07:00–19:00 h) with access to food and fresh water available ad libitum. Animal care procedures were carried out according to European Community Council Directives 86/609/EEC guidelines, and all procedures were approved by the National Animal Experiment Board (Hämeenlinna, Finland).

Transient Middle Cerebral Artery Occlusion

Animals were initially anesthetized in a gas chamber (70% N₂O and 30% O₂) with 3% halothane (Nicholas Piramal Ltd., London, UK) for 2–3 min and then maintained with 0.5–1.5% using a nose mask (Viking Medical Products, Medford Lakes, NJ, USA). Body temperature was maintained at 37°C throughout surgery by means of a heating pad connected to a rectal probe (Harvard Homeothermic Blanket Control Unit, Cambridge, MA, USA). Cerebral ischemia was induced by a filament technique (20). The right common carotid artery was exposed, and a heparinized nylon filament of Ø 0.28 mm was inserted via the stump of the external carotid artery (ECA) into the internal carotid artery (1.8–2.1 cm) to occlude the middle cerebral artery (MCA). After MCA occlusion (60 min), the filament was gently pulled out, and the ECA was closed by electrocoagulation, leaving a long ECA stump for cell transplantation. Sham-operated control animals underwent the same procedure as described above but without filament insertion. Lidocaine (2%; AstraZeneca, Espoo, Finland) was applied after closing the wound. Buprenorfine (0.03 mg/kg; RB Pharmaceuticals Ltd., Slough, Berkshire, UK) was administered for postoperative pain. Completeness of MCAO was evaluated by a modified limb-placing test before cell infusion, which shows a correlation with infarct size (25). Animals with minor behavioral impairment were excluded (n = 6). Exclusion criteria were determined before the experiment. Based on limb-placing scores, MCAO rats were also assigned to equal groups.

Preparation and Characterization of Human and Rat BM-MSCs

Human BM-MSCs were obtained from bone marrow aspirates of healthy volunteer donors (four males) after signed informed consent was gained according to the Declaration of Helsinki. The protocol was approved by the Ethics committee of the Helsinki University Central Hospital (Finland). BM-MSC establishment and characterization has been previously described (23). The cells were cultured in heparinized low-glucose Dulbecco's modified Eagle's medium (Gibco, Life Technologies Ltd., Paisley, UK), supplemented with 10% platelet-rich plasma (Finnish Red Cross Blood Service, Helsinki, Finland), 100 U/ml penicillin, and 100 μg/ml streptomycin (Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA) according to Schallmoser et al. (30). The medium was changed twice weekly, and the cultures were passaged when subconfluent (70–80% confluency) and subcultured at 1 × 10³ cells/cm². Cells were detached with trypsin (TryPLe Express, Life Technologies Ltd.). Cell viability was determined for all the samples by Trypan blue (Stem Cell Technologies, Grenoble, France) exclusion or with a Nucleocounter NC-100 (Chemometec, Allerød, Denmark). Cells [passage 2 (P2)] were cryopreserved in 180 mg/ml human serum albumin (HSA, Albunorm 200 g/L; Octapharma AG, Lachen, Switzerland) and 10% dimethyl sulfoxide (Sigma-Aldrich, Steinheim, Germany) at a cell density of 4 × 10⁶/ml.

Oricell^™ male Wistar rat BM-MSCs (Cat. No. RAWMX-01001; Cyagen Biosciences Inc., Sunnyvale, CA, USA) were cultured according to the manufacturer's instructions in OriCell MSC growth medium supplemented with 10% FBS, 1% glutamine, and 1% penicillin-streptomycin (Cat. No. GUXMX-90011; all reagents from Cyagen Biosciences Inc.). The medium was changed twice weekly, and the cultures were passaged when subconfluent (80–90% confluency) and subcultured at 1 × 10⁴ cells/cm². Rat MSCs (P5) were cryopreserved in the OriCell^™ NCR Cryopreservation Medium (Cat. No. NCPF-10001; Cyagen Biosciences Inc.) at a cell density of 4 × 10⁶/ml.

Human MSCs were analyzed for cell surface epitope expression with fluorescent-conjugated antibodies against CD73, CD90 (Stem Cell Technologies), CD105, HLA-ABC, HLA-DR, CD14, CD19, CD34, and CD45 as suggested by the International Society for Cellular Therapy (ISCT) (10). All antibodies were purchased from BD Biosciences (San Jose, CA, USA). Rat MSCs were labeled with antibodies against the markers suggested by the manufacturer, namely CD29, CD90, CD44 (all from AbD Serotec, Raleigh, NC, USA), CD11b, and CD45 (both from BD Biosciences, San Diego, CA, USA). Additionally, CD73 (BD Biosciences) expression was analyzed. Secondary antibody staining with goat anti-mouse IgG (H+L) Alexa Fluor 488 (1:500) (Molecular Probes, Life Technologies Corp., Eugene, OR, USA) was done for anti-CD73. The cells were labeled with 2–10 μ1 of the antibodies/1 × 10⁵ cells for 30 min at 4°C and run with a FACSAria flow cytometer (BD, Franklin Lakes, NJ, USA). The results were analyzed with FlowJo software (version 7.6.1; TreeStar Inc., Ashland, OR, USA). Adequate isotype control antibodies (BD Biosciences) were also used.

The cell size was measured in P2 for human MSCs and P5 for rat MSCs, that is, the same passage as used for transplantation. The analysis was done with Beckman Coulter Counter Z1 (Beckman Coulter Inc., Fullerton, CA, USA) according to the manufacturer's instructions. Briefly, the counter was calibrated with nominal latex beads (Coulter CC Size standard L10; Beckman Coulter Inc.) and for measurement, 100 μl of cell suspension, harvested at subconfluency, was diluted with 9.9 ml of phosphate-buffered saline (PBS) (all reagents from Sigma-Aldrich) containing 0.02% sodium azide (Sigma-Aldrich). The aperture range used was from 7 to 22 μm.

Labeling of Cells with ^99mTc-HMPAO

For cell labeling, the cryopreserved cells were thawed in a water bath at 37°C (16). The cells were then decanted into the thawing medium containing α-MEM (Life Technologies Ltd.) and 10% HSA. Cells were centrifuged, and medium was removed. ^99mTc-pertechnetate (2.5 GBq in 3 ml of 0.9% saline) was purchased from MAP Medical Technologies (Tikkakoski, Finland), and a HMPAO kit (Ceretec^™) was obtained from GE Healthcare Ltd. (Amersham Place, Little Chalfont, Buckinghamshire, UK). Freshly eluted ^99mTc-pertechnetate (2.5 ml, around 1.7 GBq) in saline solution was administered to a Ceretec^™ vial and mixed thoroughly, after which 1 ml of freshly prepared ^99mTc-HMPAO complex was added to 1 ml of cell suspension (approximately 10 × 10⁶ cells). Cells were incubated for 15 min at room temperature and mixed gently throughout the labeling reaction. Cells were centrifuged at 500 × g for 5 min, and the supernatant containing unbound free ^99mTc-HMPAO was removed. Cells were washed with 10 ml of PBS, centrifuged at 500 × g for 5 min, and the final radioactivity of ^99mTc-labeled cells was measured with a dose calibrator (CRC-25R; Capintec Inc., Ramsey, NJ, USA). Cells were resuspended in cell culture media and divided into 500-μl aliquots.

Cell Infusion

For cell infusion, rats were anesthetized with isoflurane (Orion Pharma Animal Health, Turku, Finland) (4% for induction, 1.2% for maintenance), and the ECA stump was exposed. ^99mTc-HMPAO-labeled rat or human BM-MSCs (2 × 10⁶ cells/animal) in 500 μl saline were slowly infused over a period of 2 min through the stump of the ECA, while the blood flow was maintained in the internal carotid artery. The ECA was closed by electrocoagulation, the wound was closed, and the animal was prepared for single-photon emission computed tomography-computed tomography (SPECT-CT) imaging.

SPECT-CT Imaging

SPECT-CT imaging was performed with a four-headed small animal scanner, NanoSPECT/CT (Bioscan Inc., Washington, DC, USA), outfitted with multipinhole collimators. The body temperature was maintained throughout the study by using a heated animal bed (Equipement Vétérinaire, Minerve, France). Whole-body SPECT images were acquired 20 min, 3 h, and 6 h postinjection in 20 projections using a time per projection of 35 s resulting in a total acquisition time of 23 min. CT imaging was carried out with a 45-kVp tube voltage with 180 projections. SPECT images were reconstructed with HiSPECT NG software (Scivis GmbH, Germany) and fused with CT datasets by using InVivoScope software (Bioscan Inc., Washington DC, USA).

Six hours after cell delivery, the rats were sacrificed, and organs were collected and stored in RIA tubes. Tissue samples were weighed, and their radioactivity was measured with a gamma counter (RiaCalc WIZ, Wallac 1480 WIZARD^® 3; Wallac Oy, Turku, Finland).

Quantification

Reconstructed SPECT images were reoriented and analyzed with the InVivoScope software by using CT data as a reference. Briefly, a three-dimensional volume of interest (VOI) was defined around the brain, lung, liver, kidney, and bladder regions. The same VOI was used for all subsequent analyses of corresponding organs. The radioactivity in each VOI was calculated and corrected to the time of injection. Results are presented as a percentage of the injected dose.

Histology

Additional sham-operated and MCAO rats were perfused for histological analysis 20 min after infusion of human BM-MSCs (baseline). Vibratome sections were stained with an antibody specific for human nuclei (MAB1281, 1:1,000; Millipore) and for endothelial cells (RECA-1, 1:1,000; AbD Serotec) to investigate possible perivascular localization of cells (23).

Statistics

The statistical analyses were done with SPSS software (IBM, Armonk, NY, USA), repeated measures ANOVA (for SPECT data), and two-way ANOVA (for radioactivity data in different organs) with cell type and sham/ MCAO operation as covariates. There were no statistically significant differences between sham-operated and MCAO rats in any measures, which allows us to combine these groups and compare rat versus human cells. Six rats received rat cells, and six rats received human cells. Differences in SPECT data and radioactivity counts between groups at various time points were analyzed by Mann– Whitney U-tests.

Results

Characterization of Human and Rat BM-MSCs

Both human and rat BM-MSCs showed the typical spindle-shaped morphology of MSCs before detachment. In the flow cytometric analysis, a set of markers defined by the ISCT was used. The human BM-MSCs were positive for MSC markers CD73, CD90, and CD105 (all >99% positive) and negative for hematopoietic lineage markers CD14, CD19, CD34, and CD45 (Fig. 1). In addition, human BM-MSCs expressed HLA-ABC (>99%) and HLA-DR (36.3%). Rat BM-MSCs were positive for CD29 (100%), CD44 (100%), CD73 (62.1%), and CD90 (99.8%), and negative for CD11b (1.3% positive) and CD45 (Fig. 1). Based on Coulter Counter measurements, the average cell size was 15–17 μm for rat and 17–18 μm for human cells.

Figure 1.

Immunophenotypic profile of human (P2) and rat (P5) BM-MSCs used in the study. Flow cytometric analysis showed the expression of CD73, CD90, CD105 HLA-ABC, and HLA-DR (dark gray histograms) on the human MSC surface compared to respective isotype controls (light gray histograms). Human BM-MSCs were negative for the expression of CD14, CD19, CD34, and CD45. Rat MSCs expressed CD29, CD44, CD73, and CD90, but not CD11b or CD45 (dark gray histograms) on the cell surface. Respective isotype controls are also shown (light gray histograms).

Efficient Accumulation of Both Human and Rat BM-MSCs in the Brain

^99mTc-HMPAO-labeled BM-MSCs were infused into the ECA 24 h after sham operation or MCAO. Representative whole-body biodistributions of rat and human BM-MSCs are shown in Figure 2 (see also supplemental figure: https://docs.google.com/drawings/d/1krdKHP_Gfu5oHqOpZpxT6SfUvdtCLveS0dQBa7wf01U/edit?usp=sharing). The majority of both the human and the rat cells were located in the brain and on the hemisphere ipsilateral to infusion shortly after cell delivery (baseline).

Figure 2.

Representative SPECT-CT images show homing of rat (A, B) and human (C, D) BM-MSCs in the brain after IA infusion. Images on the left (A, C) are for MCAO rats, and on the right (B, D), images are for sham-operated rats. The images are decay corrected and scaled to baseline.

RECA-1 and MAB1281 double immunohistochemistry at baseline showed that human BM-MSCs were located in the vascular space, and there were no signs of cell aggregation (Fig. 3). There was no statistically significant difference in the initial localization within the brain between the human and rat cells. High signal, although variable, was observed in the bladder and intestines due to the accumulation of free tracer.

Figure 3.

Histological staining of human nuclei (MAB1281) and blood vessels (RECA-1) in sham-operated (A) and MCAO (B) rats. Perfusion of animals was made 20 min after cell infusion (baseline). Human BM-MSCs were located within the brain capillaries. Scale bar: 20 μm.

Differential Clearance of BM-MSCs From the Brain

Semiquantitative analysis of different organs was used to assess cell behavior after initial accumulation in the brain. Repeated measures ANOVA showed no difference between sham-operated and MCAO rats (p = 0.817), and thus these groups were pooled. When rat and human cells were compared, ANOVA for repeated measures showed a significant overall group effect (p < 0.01) for a signal in the brain during a 6-h follow-up. A significant group × time interaction (p < 0.01) indicated differential clearance of rat and human cells from the brain. Group comparisons between MCAO rats during the follow-up showed that the signal for human BM-MSCs was lower than for rat cells (p < 0.01) at 6 h after cell delivery (Fig. 4A).

Figure 4.

Semiquantitative analysis of activity in the brain (A), liver (B), and kidney (C) after infusion of rat or human BM-MSCs. Data are decay corrected, scaled to baseline, and presented as mean ± SEM. Number of rats was six in both groups. Statistical significance: **p < 0.01 (rat vs. human cells).

There was no difference in liver (p = 0.376) or spleen (p = 0.124) signal between sham-operated and MCAO rats. ANOVA for repeated measures showed a significant group effect (p < 0.001) for a signal in the liver. In addition, a significant group × time interaction (p < 0.001) indicated differential relocation for rat and human BM-MSCs to the liver. Group comparisons during the follow-up showed that the signal for human BM-MSCs was higher (p < 0.01) at 3 and 6 h after cell delivery (Fig. 4B). Similar signal relocation was found in the kidneys. ANOVA for repeated measures showed a significant group effect (p < 0.001) and group × time interaction (p < 0.001) (Fig. 4C). Differences between human cells and rat cells were observed at 3 h and 6 h after cell delivery (p < 0.01) (Fig. 4C).

Radioactivity in Different Organs 6 h After Cell Delivery

Organs were collected for radioactivity measurements at 6 h after cell delivery (Fig. 4). There were no statistically significant differences between sham-operated and MCAO rats, and thus data from these groups were combined. Consistent with SPECT images (Figs. 2, 4), radioactivity for human BM-MSCs was significantly higher in the ipsilateral hemisphere (p < 0.05), spleen (p < 0.001), kidneys (p < 0.001), and liver (p < 0.001) (Fig. 5).

Figure 5.

Radioactivity counts as a percentage of the injected dose per organ are shown 6 h after cell infusion of rat or human BM-MSCs. The number of rats was six in both groups. Data are presented as mean ± SEM. Statistical significance: *p < 0.05; **p < 0.01; ***p < 0.001 (rat vs. human cells).

Discussion

Determining the whole-body biodistribution of infused cells is critical for the development of intravascular cell therapies. In this study, we showed that SPECT imaging provides fast and effective information about cell biodistribution and that xenotransplantation has a major effect on cell clearance from the brain in a rat model of stroke, which should be taken into careful consideration when planning safety and efficacy studies for cell therapy products.

There have been significant improvements in small animal SPECT systems over recent years; for example, the imaging resolution is now less than 1 mm, and tracer concentrations in the picomolar or nanomolar range can be detected (26). SPECT is also a translational imaging modality, and the tracers used in animal studies are used in clinical practice. Still, only a few studies have taken advantage of SPECT for cell tracking in stroke models, possibly due to safety issues (2,17,21,23). Cells are affected by low-energy high-linear energy transfer Auger electron emitting ^99mTc, although not to the extent of that in the case of radioactive ¹¹¹In (26). According to Haefliger et al. (12), the radioactivity of ^99mTc below the level of 466 Bq/cell had almost no effect on cell proliferation. In our study, the radioactivity of ^99mTc was 0.3–14 Bq/cell, which was not considered to be radiotoxic. However, cell viability testing is essential particularly if long-term functional outcome will be studied.

Here we showed efficient entrapment of both rat and human BM-MSCs to the brain shortly after IA infusion by using SPECT imaging. No difference between sham-operated and MCAO rats was observed, indicating that inflammatory signals present in the brain at 24 h after MCAO do not explain the results. The described cell behavior is intriguingly similar to the cell entrapment seen in the lungs following IV cell administration (11). Both cell size and adhesion molecule expression seem to contribute to pulmonary entrapment, which is considered to be the main obstacle impairing efficient cell homing to target tissue. We cannot exclude the possibility that IA infused cells cause blockage of small vessels and brain tissue damage as suggested by Janowski et al. (15). However, this is not supported by histological staining of human BM-MSCs shortly after IA infusion. Only a few scattered cells were observed within vasculature or the brain parenchyma at 24 h after infusion in our previous study (23).

To our surprise, the clearance of cells from the brain tissue was extremely fast. After 6 h, only 58% of the signal related to rat cells was left. In addition, human BM-MSCs disappeared much faster than rat cells. The size of the rat and human BM-MSCs is the same, and thus the cell size does not seem to determine the differential clearance. Interestingly, Brenneman et al. (7) showed a similar disappearance of autologous BM-mononuclear cells in a permanent MCAO rat model. The remaining cells were TUNEL positive 3 h after infusion, indicating a rapid necrotic/apoptotic process. Rosenblum et al. (28) showed that, in a mouse stroke model, therapeutic cells were more likely to be phagocytosed when infused within the first 24 h after hypoxia–ischemia, which may also contribute toward graft cell disappearance. Cells (dead and alive) are eliminated from the body in the liver and spleen, and thus high signal in these organs could reflect the elimination process (23). Consistent with this, detachment of the ^99mTc due to cell death results in high signal in the bladder and intestine.

One explanation for the different clearance of human cells compared to rat BM-MSCs from the brain could be that human cells induce an immunological response much faster than rat allogeneic cells, which could lead to rapid rejection of the cells (5). Current studies lack information on the immunological responses to cell administration in the rat stroke model, and the existing data are inconsistent. Human MSC engraftment and survival have been shown in the brains of rats with partially impaired immune systems (3). Comparisons of human and rat allogeneic BM-MSCs showed that both cells elicited only a weak immune response after transplantation, and cells survived for at least 3 months in the host brain (29). Similar findings have been shown in xenotransplantation of mouse MSCs to the intact and ischemic rat brain, although immunosuppression could improve graft survival (14). Contradictory findings suggest that even allogeneic BM-MSCs could be rejected in the healthy rat brain (9).

Whether BM-MSCs evoke immunological reactions or not, functional recovery using human BM-MSCs in rat brain ischemia models has been shown in several studies (1,8,19,34,35). According to Yang et al. (34), systemic administration of either rat or human MSCs was equally beneficial in enhancing motor recovery in MCAO rats, although very few MSCs were found in the brain. In addition, a recent review gathered data from 94 reports to show that in 88 cases MSCs could function in several different cross-species models, indicating that these cells might overcome xenobarriers (18). One explanation could be that MSCs exert their therapeutic effects through a “hit and die” mechanism, that is, rapid migration to the damaged organ and subsequent clearance accompanied with the release of therapeutic molecules. In that case even xenogeneic cells could have enough time to be therapeutic, although they are rather rapidly rejected. The fact that even allogeneic MSCs will be eventually rejected can, in fact, limit the long-term risks of MSC therapy (31,32).

In conclusion, our study suggests that xenografting has an impact on cell clearance from the brain and faster relocation of human MSCs compared to rat MSCs to the liver and spleen in animals. This decreases the bioavailability of cells in the target tissue as well as their therapeutic effect. Overall, the complexity of immunological processes, differences of immune systems between species, and uncertainty behind the exact mechanisms of how MSCs influence these processes makes it difficult to make broad conclusions. Thus, controlled comparative studies of the therapeutic effect and immunological responses between human versus allogeneic MSCs in experimental stroke models are urgently needed. Homologous animal models may provide the most relevant system for proof-of-concept, while xenogeneic models are essential for safety studies. The existing limitations require careful interpretation of data.

Footnotes

Acknowledgments

We would like to thank Sirkka Hirschovits-Gerz, Susanna Räsänen, Lotta Sankkila, and Sofia Oja for their technical assistance with animal care and cell culture. Eero Hippeläinen is acknowledged for professional help with SPECT images. This research work was supported by the Health Research Council of the Academy of Finland and by a grant of the Academy of Finland (263171) in the framework of the ERA-NET NEURON. The authors declare no conflicts of interest.

References

Andrews

E. M.

Tsai

S. Y.

Johnson

S. C.

Farrer

J. R.

Wagner

J. P.

Kopen

G. C.

Kartje

G. L.

Human adult bone marrow-derived somatic cell therapy results in functional recovery and axonal plasticity following stroke in the rat. Exp. Neurol. 211: 588–592; 2008.

Arbab

A. S.

Thiffault

Navia

Victor

S. J.

Hong

Zhang

Jiang

Varma

N. R. S.

Iskander

A. S. M.

Chopp

Tracking of In-111-labeled human umbilical tissue-derived cells (hUTC) in a rat model of cerebral ischemia using SPECT imaging. BMC Med. Imaging 12: 33; 2012.

Azizi

S. A.

Stokes

Augelli

B. J.

DiGirolamo

Prockop

D. J.

Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats-similarities to astrocyte grafts. Proc. Natl. Acad. Sci. USA. 95: 3908–3913; 1998.

Banerjee

Williamson

D. A.

Habib

Chataway

The potential benefit of stem cell therapy after stroke: An update. Vasc. Health Risk Manag. 8: 569–580; 2012.

Barker

R. A.

Widner

Immune problems in central nervous system cell therapy. NeuroRx 1: 472–481; 2004.

Bonita

Solomon

Broad

J. B.

Prevalence of stroke and stroke-related disability. Estimates from the Auckland stroke studies. Stroke 28: 898–902; 1997.

Brenneman

Sharma

Harting

Strong

Cox

C. S.

Jr. Aronowski

Grotta

J. C.

Savitz

S. I.

Autologous bone marrow mononuclear cells enhance recovery after acute ischemic stroke in young and middle-aged rats. J. Cereb. Blood Flow Metab. 30: 140–149; 2010.

Chen

Wang

Zhang

Chopp

Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J. Neurol. Sci. 189: 49–57; 2001.

Coyne

T. M.

Marcus

A. J.

Woodbury

Black

I. B.

Marrow stromal cells transplanted to the adult brain are rejected by an inflammatory response and transfer donor labels to host neurons and glia. Stem Cells. 24: 2483–2492; 2006.

10.

Dominici

Le Blanc

Mueller

Slaper-Cortenbach

Marini

Krause

Deans

Keating

Prockop

D. J.

Horwitz

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315–317; 2006.

11.

Fischer

U. M.

Harting

M. T.

Jimenez

Monzon-Posadas

W. O.

Xue

Savitz

S. I.

Laine

G. A.

Cox

C. S.

Jr. Pulmonary passage is a major obstacle for intravenous stem cell delivery: The pulmonary first-pass effect. Stem Cells Dev. 18: 683–692; 2009.

12.

Haefliger

Agorastos

Renard

Giambonini-Brugnoli

Marty

Alberto

Cell uptake and radiotoxicity studies of an nuclear localization signal peptideintercalator conjugate labeled with [99mTc(CO)3]+. Bioconjug. Chem. 16: 582–587; 2005.

13.

Hess

D. C.

Hill

W. D.

Cell therapy for ischaemic stroke. Cell Prolif. 44(Suppl 1): 1–8; 2011.

14.

Irons

Lind

J. G.

Wakade

C. G.

Hadman

Carroll

Hess

D. C.

Borlongan

C. V.

Intracerebral xenotransplantation of GFP mouse bone marrow stromal cells in intact and stroke rat brain: Graft survival and immunologic response. Cell Transplant. 13: 283–294; 2004.

15.

Janowski

Lyczek

Engels

Lukomska

Bulte

J. W.

Walczak

Cell size and velocity of injection are major determinants of the safety of intracarotid stem cell transplantation. J. Cereb. Blood Flow Metab. 33: 921–927; 2013.

16.

Kerkelä

Hakkarainen

Mäkelä

Raki

Kambur

Kilpinen

Nikkilä

Lehtonen

Ritamo

Pernu

Pietilä

Takalo

Juvonen

Bergström

Kalso

Valmu

Laitinen

Lehenkari

Nystedt

Transient proteolytic modification of mesenchymal stromal cells increases lung clearance rate and targeting to injured tissue. Stem Cells Transl. Med. 2: 510–520; 2013.

17.

Lappalainen

Narkilahti

Huhtala

Liimatainen

Suuronen

Närvänen

Suuronen

Hovatta

Jolkkonen

SPECT imaging shows accumulation of stem cells into internal organs after systemic administration in middle cerebral artery occlusion rats. Neurosci. Lett. 440: 246–250; 2008.

18.

Ezzelarab

M. B.

Cooper

D. K.

Do mesenchymal stem cells function across species barriers? Relevance for xenotransplantation. Xenotransplantation 19: 273–285; 2012.

19.

Chen

X. G.

Wang

Gautam

S. C.

Y. X.

Katakowski

Zhang

L. J.

Janakiraman

Chopp

Human marrow stromal cell therapy for stroke in rat: Neurotrophins and functional recovery. Neurology 59: 514–523; 2002.

20.

Longa

E. Z.

Weinstein

P. R.

Carlson

Cummins

Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84–91; 1989.

21.

Mäkinen

Kekarainen

Nystedt

Liimatainen

Huhtala

Närvanen

Laine

Jolkkonen

Human umbilical cord blood cells do not improve sensorimotor or cognitive outcome following transient middle cerebral artery occlusion in rats. Brain Res. 1123: 207–215; 2006.

22.

Mendez-Otero

de Freitas

G. R.

Andre

de Mendonca

M. L.

Friedrich

Oliveira Filho

Potential roles of bone marrow stem cells in stroke therapy. Regen. Med. 2: 417–423; 2007.

23.

Mitkari

Kerkelä

Nystedt

Korhonen

Huhtala

Jolkkonen

Intra-arterial infusion of human bone marrow-derived mesenchymal stem cells result in transient localization in the brain after cerebral ischemia in rats. Exp. Neurol. 239: 158–162; 2013.

24.

Molina

C. A.

Reperfusion therapies for acute ischemic stroke: Current pharmacological and mechanical approaches. Stroke 42: S16–19; 2011.

25.

Mäkinen

Kekarainen

Nystedt

Liimatainen

Huhtala

Närvanen

Laine

Jolkkonen

Human umbilical cord blood cells do not improve sensorimotor or cognitive outcome following transient middle cerebral artery occlusion in rats. Brain Res. 1123: 207–215; 2006.

26.

Puurunen

Jolkkonen

Sirviö

Haapalinna

Sivenius

An α2-antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats. Neuropharmacology 40: 597–606; 2001.

27.

Raki

Bergström

Jolkkonen

In vivo biodistribution studies and cell tracking in stroke using SPECT imaging. In: Jolkkonen

Walczak

eds. Cell-Based Therapies in Stroke. Vienna, Austrai: Springer; 2013: 137–149.

28.

Rosado-de-Castro

P. H.

Pimentel-Coelho

P. M.

Barbosa da Fonseca

L. M.

de Freitas

G. R.

Mendez-Otero

Stem Cells Dev. 22: 2095–2111; 2013.

29.

Rosenblum

Wang

Smith

T. N.

Pendharkar

A. V.

Chua

J. Y.

Birk

Guzman

Timing of intra-arterial neural stem cell transplantation after hypoxia-ischemia influences cell engraftment, survival, and differentiation. Stroke 43: 1624–1631; 2012.

30.

Rossignol

Boyer

Thinard

Remy

Dugast

A. S.

Dubayle

Dey

N. D.

Boeffard

Delecrin

Heymann

Vanhove

Anegon

Naveilhan

Dunbar

G. L.

Lescaudron

Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xeno-transplantation. J. Cell Mol. Med. 13: 2547–2558; 2009.

31.

Schallmoser

Bartmann

Rohde

Reinisch

Kashofer

Stadelmeyer

Drexler

Lanzer

Linkesch

Strunk

Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 47: 1436–1446; 2007.

32.

Uccelli

Moretta

Pistoia

Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8: 726–736; 2008.

33.

von Bahr

Batsis

Moll

Hägg

Szakos

Sundberg

Uzunel

Ringden

Le Blanc

Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells. 30: 1575–1578; 2012.

34.

Willing

A. E.

Shahaduzzaman

Delivery routes for cell therapy in stroke. In: Jolkkonen

Walczak

eds. Cell-Based Therapies in Stroke. Vienna, Austrai: Springer; 2013: 15–28.

35.

Yang

Wei

Heine

L. A.

Rosenwasser

Iacovitti

Changes in host blood factors and brain glia accompanying the functional recovery after systemic administration of bone marrow stem cells in ischemic stroke rats. Cell Transplant. 19: 1073–1084; 2010.

36.

Zhao

L. R.

Duan

W. M.

Reyes

Keene

C. D.

Verfaillie

C. M.

Low

W. C.

Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp. Neurol. 174: 11–20; 2002.

Differential Clearance of Rat and Human Bone Marrow-Derived Mesenchymal Stem Cells from the Brain after Intra-arterial Infusion in Rats

Abstract

Keywords

Introduction

Materials and Methods

Animals

Transient Middle Cerebral Artery Occlusion

Preparation and Characterization of Human and Rat BM-MSCs

Labeling of Cells with 99mTc-HMPAO

Cell Infusion

SPECT-CT Imaging

Quantification

Histology

Statistics

Results

Characterization of Human and Rat BM-MSCs

Efficient Accumulation of Both Human and Rat BM-MSCs in the Brain

Differential Clearance of BM-MSCs From the Brain

Radioactivity in Different Organs 6 h After Cell Delivery

Discussion

Footnotes

Acknowledgments

References

Labeling of Cells with ^99mTc-HMPAO